Work

The next decade in cell and gene therapy

Year: 2025

Type: article

Abstract: • By 2034, approximately 79 new durable cell and gene approvals are projected. • The number of patients treated by 2034 is projected to increase nearly tenfold. • The 2034 list price revenue of these new approvals are projected at $28.8 billion. In the 8 years since the US Food and Drug Administration (FDA) approved the first durable cell and gene therapy (dCGT), there have been over 32 product-indication approvals, with many more products and indications in the pipeline. Using a novel multi-modal Markov chain Monte Carlo (MCMC)-based model, we estimate that, by 2034, the pipeline will yield ∼79 new product-indication approvals, an annual average of 29% year-over-year growth in treated patients, and US$28.8 billion in list price drug revenues, before any healthcare cost offsets, caregiving impacts, long-term social benefits, or other benefits from treating these additional patients.

Source: Drug Discovery Today

DOI: 10.1016/j.drudis.2025.104551

Authors: Sharon E. Phares, Colin M. Young, Katie I. Phillip, Mark R. Trusheim

Institution: Tufts Medical Center

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,720